Indravadan Ambalal Modi, known as the “Medicine Man of India,” founded Cadila Pharmaceuticals with one unwavering conviction: modern medicine must be affordable and accessible to the last man in society. More than seven decades later, the company he built remains one of India’s largest privately held pharmaceutical firms, present in over 100 countries, generating INR 3,870 crore (~$455 million) in FY25 revenue, and answerable to no stock exchange. This is not Zydus Lifesciences. The two companies share a historical origin but have operated as completely independent entities for decades.
Indravadan Ambalal Modi (1926–2012) did not merely build a pharmaceutical company. He helped reshape the legal architecture that made Indian generics possible. Modi was among the most vocal champions of the Indian Patents Act of 1970, the legislation that replaced product patents with process patents and opened the door for India’s generic pharmaceutical industry to emerge. Without that law, the ecosystem that now supplies affordable medicines to billions of people worldwide might never have taken shape.
His founding vision was plain-spoken and absolute: “making modern medicine affordable and accessible to the last man in society.” That was not a marketing slogan. It was an operational directive that guided every expansion decision, every therapeutic choice, and every market entry the company undertook during his lifetime. Under Modi’s leadership, Cadila Pharmaceuticals grew from a single facility in Ahmedabad into a multi-continent operation with presence across all major regulated markets.
Modi passed away in 2012, but the company he built continues to operate under the same privately held structure he insisted upon, free from the quarterly pressures of public markets and answerable to the founding family’s long-term vision rather than institutional shareholders.
Most Indian pharmaceutical companies of Cadila Pharmaceuticals’ scale are publicly listed. The pressures of quarterly earnings calls, analyst expectations, and share price management shape their strategic decisions in ways both visible and invisible. Cadila Pharmaceuticals has chosen a different path entirely. As one of India’s largest privately held pharma companies, it operates with a time horizon that public companies cannot match.
That private structure has not limited the company’s geographic ambition. Cadila Pharmaceuticals is present in more than 100 countries spanning every major regulated market: the United States, Europe, Japan, Africa, and beyond. The company maintains approximately 5,400 employees, with some estimates placing the global workforce closer to 9,000 when including roughly 200 personnel stationed outside India. This is a genuinely global operation built without a single public share offering.
Headquartered in Ahmedabad, the company also operates contract development and manufacturing (CDMO/CMO) services alongside contract research, adding revenue streams that leverage its manufacturing infrastructure and regulatory expertise without the commercial risk of branded launches in unfamiliar markets.
Cadila Pharmaceuticals concentrates its therapeutic focus in areas where India bears an enormous disease burden: gastroenterology, cardiology, gynaecology, diabetology, and oncology. These are not peripheral therapy areas chosen for commercial convenience. They represent the conditions that affect hundreds of millions of patients across the markets where the company operates.
The research operation employs more than 350 scientists working across drug discovery and formulation development. The company claims first-in-world innovations spanning lung cancer, tuberculosis, cardiovascular disease, and gastroenterology, a breadth of discovery work that is unusual for a privately held generics-focused firm. The research infrastructure supports both the company’s own product pipeline and its contract research services for external clients.
What distinguishes the R&D effort is its alignment with the founder’s original mission. The therapeutic areas Cadila Pharmaceuticals prioritises are precisely those where affordable alternatives have the greatest public health impact, conditions that are chronic, widespread, and disproportionately concentrated in low- and middle-income populations.
Operating in every major regulated market simultaneously requires manufacturing facilities that can withstand inspection from multiple regulatory agencies with different standards, different expectations, and different enforcement cultures. Cadila Pharmaceuticals’ manufacturing operations comply with requirements from the US FDA, the European Union, the UK’s MHRA, WHO Geneva, and Australia’s TGA.
Multi-regulatory compliance at this level is not a checkbox exercise. Each agency brings its own inspection methodology, its own documentation requirements, and its own expectations around corrective action. Maintaining simultaneous compliance across all of them demands a quality management system that meets the highest common denominator rather than the lowest, because a facility approved by WHO Geneva must also satisfy the more granular expectations of the US FDA and the EU’s centralised procedures.
For a privately held company, sustaining this level of regulatory investment is a deliberate strategic choice. Public companies can point to FDA approvals in earnings presentations. Cadila Pharmaceuticals maintains the same standards without that external incentive, because access to regulated markets is the mechanism through which the founder’s mission of global accessibility is actually delivered.
Sources: Cadila Pharmaceuticals corporate disclosures and company website. Industry directories and pharmaceutical trade publications. Regulatory compliance data from USFDA, EU, MHRA, WHO Geneva, and TGA.